Pacira Pharmaceuticals Inc-DE
Geschlossen
BrancheGesundheitswesen
23.83 1.02
Übersicht
Veränderung der Aktienkurses
24h
Min
23.4
Max
24.18
Einkommen | 1.3M 2.9M |
|---|---|
Verkäufe | -19M 177M |
KGV Branchendurchschnitt | 174.692 50.958 |
EPS | 0.6 |
Gewinnspanne | 1.644 |
Angestellte | 825 |
EBITDA | 5M 30M |
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +26.54% upside |
Nächstes Ergebnis | 4. Aug. 2026 |
|---|
Marktkapitalisierung | -206M 894M |
|---|---|
Vorheriger Eröffnungskurs | 22.81 |
Vorheriger Schlusskurs | 23.83 |
Nachrichtenstimmung
By Acuity
67%
33%
295 / 342 Ranking in Healthcare
Pacira Pharmaceuticals Inc-DE Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Pacira Pharmaceuticals Inc-DE
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.